AI summary · may contain errors
Daraxonrasib, a first-in-class pan-RAS inhibitor, shrank tumors in more than 30% of previously treated RAS-mutant non-small cell lung cancer patients.
- In the news
Moving in Cancer Discovery and New England Journal of Medicine.
Rebuilt
AI summary · may contain errors
Daraxonrasib, a first-in-class pan-RAS inhibitor, shrank tumors in more than 30% of previously treated RAS-mutant non-small cell lung cancer patients.
AI summary · may contain errors
A germline EGFRT790M variant linked to lung cancer is concentrated in Southern Appalachia, reflecting its introduction to the United States by European settlers in the 1700s.
AI summary · may contain errors
First-line sunvozertinib improves progression-free survival versus carboplatin-pemetrexed in advanced nonsquamous NSCLC with EGFR exon 20 insertions, reaching 10.3 vs 7.5 months.
Newest first · last 60 days
AI summary · may contain errors
A non-small-cell lung cancer manuscript was withdrawn because an isoform re-expression construct was misidentified as HK1b variant 8 instead of HK1 variant 1.
AI summary · may contain errors
CDKN2A/MTAP deletion (CMdel) occurs in 11.7% of NSCLC patients and defines a genomically distinct subset enriched for actionable drivers and worse outcomes on ICI/chemotherapy.
AI summary · may contain errors
MTAP loss is among the most common potentially targetable driver mutations in non-small cell lung cancer (NSCLC), supporting ongoing early-phase trials.
AI summary · may contain errors
KRAS Q61-mutant non-small cell lung cancer shows clinically relevant differences between Q61 alleles, emphasizing that genomic context matters for interpreting these mutations.
AI summary · may contain errors
ERBB2 activating mutations in HER2-non-amplified metastatic breast cancer are linked to longer trastuzumab deruxtecan rwPFS, with 11 versus 6.2 months versus wild-type.
AI summary · may contain errors
MTAP-deleted advanced non-small cell lung cancer shows worse progression-free survival than MTAP wild-type on anti-PD-(L)1–based regimens, with hazard ratios up to 1.89.
AI summary · may contain errors
In anti-PD-(L)1 resistant advanced non-small cell lung cancer, ceralasertib plus durvalumab shows modestly higher 24-week durable clinical benefit in KRAS-mutant (37.7%) than KRAS-wild type (29.3%).
AI summary · may contain errors
In 365 patients with non-small cell lung cancer harboring KRAS Q61 mutations, median overall survival was 12.3 months, with first-line immunotherapy linked to longer survival.
AI summary · may contain errors
Spatial profiling of resected non-small cell lung cancer tumors and lymph nodes identified immune subtypes and a gene signature linked to improved outcomes.
AI summary · may contain errors
Histological transformation is a key resistance mechanism in precision oncology, linked to tumor plasticity that can erode clinical benefit after initial success with targeted therapies.
AI summary · may contain errors
RNA sequencing of 1,824 lung cancer tumors defines nine transcriptional clusters spanning adenocarcinoma, squamous, and small cell, including a neuroendocrine-like adenocarcinoma group.
AI summary · may contain errors
Low-order multimerization of cytoplasmic RTK fusions drives strong Ras-Erk signalling and transformation without mesoscale condensation, including for EML4-ALK where signalling poorly correlates with condensates.
AI summary · may contain errors
Baseline PD-L1 and TP53 combined with TSG are linked to very-early progression on first-line osimertinib monotherapy in EGFR-mutant NSCLC, with PD-L1 TPS showing the strongest signal.
AI summary · may contain errors
Mild immune-related hepatitis (grade 1–2) in 3261 East Asian lung cancer patients treated with ICIs predicts longer overall survival, with onset at 2.17 months.
AI summary · may contain errors
EGFR P-loop/αC-helix compressing (PACC) mutations and exon 20 insertions (ex20ins) form distinct kinase-domain subsets with reduced sensitivity to EGFR TKIs for classical sensitizing mutations.
AI summary · may contain errors
MTAP loss is detected in 17% of 243 non-small cell lung cancers, including 24% of stage 4 driver-positive tumors, highlighting a frequent, actionable biomarker.
AI summary · may contain errors
Ruzaltatug rezetecan significantly improved BICR-assessed progression-free survival versus chemotherapy in 498 Chinese patients with EGFR-mutated advanced NSCLC after EGFR TKI progression.
AI summary · may contain errors
Dose interruptions of four or more consecutive days in US FDA trial populations of NSCLC with EGFR mutations are more often linked to higher progression or death risk than dose reductions.
AI summary · may contain errors
ENPP1 expression is significantly upregulated in established osimertinib-resistant NSCLC tumor models, and this elevation is linked to suppression of the cGAS-STING pathway via extracellular cGAMP hydrolysis.
AI summary · may contain errors
Soxataltinib produced an IRC-assessed 84.8% ORR (95% CI 76.4–91.0) in treatment-naïve and previously treated advanced RET fusion-positive NSCLC at median 19.3-month follow-up.
AI summary · may contain errors
HB0025 plus chemotherapy produced confirmed objective response rates of 36.4% and 57.1% in previously untreated driver variant-negative nonsquamous advanced NSCLC, with manageable toxicity.
AI summary · may contain errors
Neoadjuvant perioperative ivonescimab plus chemotherapy in resectable non-small cell lung cancer achieved a 70.1% major pathological response rate (47/67), meeting the primary endpoint.
AI summary · may contain errors
In a real-world cohort of 265 U.S. patients with small cell lung cancer, tarlatamab achieved a 52.6% disease control rate and median rw-PFS of 2.3 months.
Journals this month
Topics moving, week to 18 Nov 2026
By field